ANDAs Must Show Inactive Ingredient Changes Do Not Affect Efficacy - FDA
Executive Summary
Applications for generic drug products with different inactive ingredients than the innovator drug must demonstrate that efficacy is unaffected, FDA said in its proposed rule revising the regulation on bioequivalence/bioavailability and the content and format of abbreviated new drug applications.